User login
This supplement to Neurology Reviews features an interview with Stewart J. Tepper, MD, who reviews promising data on monoclonal antibodies that target calcitonin gene-related peptide (CGRP) and discusses how the introduction of these treatments is benefitting patients with migraine.
"These medications can manifest very different levels of efficacy, safety, and tolerability than we've ever seen before. What I'm seeing in practice can be jaw-dropping." - Stewart J. Tepper, MD
This supplement to Neurology Reviews features an interview with Stewart J. Tepper, MD, who reviews promising data on monoclonal antibodies that target calcitonin gene-related peptide (CGRP) and discusses how the introduction of these treatments is benefitting patients with migraine.
"These medications can manifest very different levels of efficacy, safety, and tolerability than we've ever seen before. What I'm seeing in practice can be jaw-dropping." - Stewart J. Tepper, MD
This supplement to Neurology Reviews features an interview with Stewart J. Tepper, MD, who reviews promising data on monoclonal antibodies that target calcitonin gene-related peptide (CGRP) and discusses how the introduction of these treatments is benefitting patients with migraine.
"These medications can manifest very different levels of efficacy, safety, and tolerability than we've ever seen before. What I'm seeing in practice can be jaw-dropping." - Stewart J. Tepper, MD
